Kiniksa Pharmaceuticals International (KNSA) Gross Profit (2021 - 2026)

Kiniksa Pharmaceuticals International has reported Gross Profit for 6 years, with the latest figure at $193.5 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 61.34% year-over-year to $193.5 million; the trailing twelve-month figure through Mar 2026 stood at $673.4 million (up 63.07% YoY), and the FY2025 full-year result was $599.9 million, up 65.57% from the prior year.
• Gross Profit for Q1 2026 stood at $193.5 million, up from $181.2 million in the prior quarter.
• The five-year high for Gross Profit was $193.5 million in Q1 2026, with the low at -$155.0 million in Q4 2022.
• Historically, Gross Profit has averaged $81.5 million across 5 years, with a median of $92.1 million in 2024.
• The largest YoY upside for Gross Profit was 888.4% in 2022 against a maximum downside of 769.77% in 2022.
• Kiniksa Pharmaceuticals International's Gross Profit stood at -$155.0 million in 2022, then jumped by 147.62% to $73.8 million in 2023, then surged by 41.77% to $104.6 million in 2024, then soared by 73.15% to $181.2 million in 2025, then climbed by 6.78% to $193.5 million in 2026.
• The last three Gross Profit figures came in at $193.5 million (Q1 2026), $181.2 million (Q4 2025), and $160.6 million (Q3 2025), per Business Quant data.